Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in radioimmunotherapy and antibody-based cancer treatments, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Michael Rossi, President and CEO, will deliver a presentation on January 15, 2025, at 5:15 p.m. PT in San Francisco.
The presentation will be accessible via live webcast through the Events section of Y-mAbs' investor relations website at ir.ymabs.com. The recording will remain available for replay for 30 days following the event.
Y-mAbs Therapeutics (Nasdaq: YMAB), un'azienda biofarmaceutica in fase commerciale specializzata in radioimmunoterapia e trattamenti antitumorali basati su anticorpi, ha annunciato la sua partecipazione alla 43ª Conferenza Sanitaria Annuale J.P. Morgan. Michael Rossi, Presidente e CEO, presenterà il suo intervento il 15 gennaio 2025, alle 17:15 PT a San Francisco.
La presentazione sarà accessibile tramite webcast dal vivo attraverso la sezione Eventi del sito web per le relazioni con gli investitori di Y-mAbs all'indirizzo ir.ymabs.com. La registrazione rimarrà disponibile per il replay per 30 giorni dopo l'evento.
Y-mAbs Therapeutics (Nasdaq: YMAB), una compañía biofarmacéutica en etapa comercial especializada en radioinmunoterapia y tratamientos contra el cáncer basados en anticuerpos, ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica J.P. Morgan. Michael Rossi, Presidente y CEO, ofrecerá una presentación el 15 de enero de 2025, a las 5:15 p.m. PT en San Francisco.
La presentación será accesible a través de un webcast en vivo en la sección de Eventos del sitio web de relaciones con inversores de Y-mAbs en ir.ymabs.com. La grabación estará disponible para su reproducción durante 30 días después del evento.
Y-mAbs Therapeutics (Nasdaq: YMAB), 항체 기반 암 치료 및 방사면역요법을 전문으로 하는 상장 바이오 제약 회사가 제43회 연례 J.P. 모건 헬스케어 콘퍼런스에 참여한다고 발표했습니다. 마이클 로시, 사장 겸 CEO가 2025년 1월 15일 오후 5시 15분 PT에 샌프란시스코에서 발표를 진행합니다.
발표는 Y-mAbs의 투자자 관계 웹사이트 ir.ymabs.com의 이벤트 섹션을 통해 라이브 웹캐스트로 액세스할 수 있습니다. 이벤트 이후 30일 동안 재생을 위해 녹화가 제공됩니다.
Y-mAbs Therapeutics (Nasdaq: YMAB), une entreprise biopharmaceutique en phase commerciale spécialisée dans la radio-immunothérapie et les traitements anticancéreux basés sur des anticorps, a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan Healthcare. Michael Rossi, Président et PDG, fera une présentation le 15 janvier 2025, à 17h15 PT à San Francisco.
La présentation sera accessible par webcast en direct via la section Événements du site web des relations avec les investisseurs de Y-mAbs à l'adresse ir.ymabs.com. L'enregistrement sera disponible en replay pendant 30 jours suivant l'événement.
Y-mAbs Therapeutics (Nasdaq: YMAB), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf Radioimmuntherapie und antikörperbasierte Krebsbehandlungen spezialisiert hat, hat seine Teilnahme an der 43. J.P. Morgan Healthcare Conference bekannt gegeben. Michael Rossi, Präsident und CEO, wird am 15. Januar 2025, um 17:15 Uhr PT in San Francisco eine Präsentation halten.
Die Präsentation wird über Live-Webcast im Event-Bereich der Investor-Relations-Website von Y-mAbs unter ir.ymabs.com zugänglich sein. Die Aufzeichnung wird 30 Tage nach der Veranstaltung für eine Wiederholung verfügbar sein.
- None.
- None.
NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025 at 5:15 p.m. PT.
A live webcast will be available under the Events section of the Company’s investor relations website at ir.ymabs.com. The webcast will be archived and available for replay for 30 days after the event.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2024 and beyond.Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will,” ‘‘would’,’ “guidance,” “goal,” “objective,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company’s business is subject to risks and uncertainties affecting the Company including those described in the “Risk Factors” section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and the Company’s Quarterly Report on Form 10-Q for the quarterly periods ended March 31, 2024, and September 30, 2024, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
SADA®, SADA PRIT®, DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc.
Investor Contact:
Courtney Dugan
VP, Head of Investor Relations
cdu@ymabs.com
FAQ
When is Y-mAbs (YMAB) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Y-mAbs' (YMAB) J.P. Morgan Healthcare Conference presentation?
How long will Y-mAbs' (YMAB) J.P. Morgan Conference presentation replay be available?
Who will represent Y-mAbs (YMAB) at the 2025 J.P. Morgan Healthcare Conference?
What type of therapeutic products does Y-mAbs (YMAB) develop?
